Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes.
Clinical trials with tacrine (THA) and its principal (1-OH) metabolite (velnacrine) for the treatment of Alzheimer's disease have been hampered by adverse hepatic events that were undetected in preclinical studies. As part of integrated in vivo/in vitro efforts to characterize the role of metabolites in these events, cultured cells were evaluated for their suitability for further mechanistic studies. The relative cytotoxic potentials of THA, three monohydroxy metabolites of THA (including velnacrine, a racemate), the two velnacrine enantiomers, and several known and suspected dihydroxy velnacrine metabolites were determined. Cytotoxicity was evaluated in 24-hour cultures by morphology and by the Neutral Red Uptake Assay. All test articles were evaluated in primary rat hepatocytes and in a human hepatoma cell line (HepG2). THA and velnacrine were also tested in a rat hepatoma cell line (H4) and in primary dog hepatocytes. The metabolic competency of each cell type was determined. Sensitivity to THA and velnacrine was greatest in H4 cells, followed by primary rat and HepG2 cells; dog cells were least sensitive. In HepG2 cells, THA was clearly more cytotoxic (LC50:54 micrograms/ml) than its monohydroxy metabolites (LC50 values: 84 to 190 micrograms/ml); dihydroxy velnacrine metabolites were the least cytotoxic (LC50 values:251 to 434 micrograms/ml); the relative order was comparable in primary rat hepatocytes. Roles for reactive metabolites and/or altered metabolic capabilities of Alzheimer's patients are suggested.
Viau
C J
CJ
Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ 08876.
Curren
R D
RD
Wallace
K
K
D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000633:toxicity*; D004285:Dogs; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000166:cytology* / Q000187:drug effects* / Q000201:enzymology; D008107:Liver Diseases / Q000201:enzymology; D008113:Liver Neoplasms / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000378:metabolism; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D012680:Sensitivity and Specificity; D013619:Tacrine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D013619:Tacrine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C056424:velnacrine